on Viromed Medical AG (isin : DE000A3MQR65)
Viromed Medical AG Restructures Management for Growth
Viromed Medical AG, a leader in cold plasma technology, announces a significant restructuring of its Management Board. Founder Uwe Perbandt will resign by the end of December 2026. Christian Strauch will join the board on November 16, 2026, for a nearly three-year term. Strauch is expected to guide Viromed through its next growth phase with his substantial sales expertise.
The Supervisory Board, led by Dr. Thomas Gutschlag, is committed to this strategic transition. Strauch's extensive experience in scaling healthcare companies, including his roles with pharmedix GmbH and other pharmaceutical ventures, positions him as a valuable asset for Viromed's future.
Perbandt expressed pride in Viromed's achievements and confidence in Strauch as his successor. With a solid foundation in place, the company is poised to expand the application of its technology and capitalize on emerging market opportunities.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Viromed Medical AG news